4DMedical

Melbourne, Victoria, Australia, with offices in Los Angeles, California, United States.  All United States companies → — Founded 2012
Imaging AI Specialist Medical Device / Hardware Specialty-Focused AI
Cardiology Pulmonology Radiology
Cardiology AI Radiology & Imaging AI
Publicly Traded (ASX: 4DX), formerly VC-backed. — Over US$100 million (AU$150 million) in new institutional placement as of January/February 2026.

Products

4DMedical (Imbio)
4DMedical
Cardiology AI
4DMedical, with its acquisition of Imbio, offers a comprehensive suite of AI-driven medical imaging solutions for chronic lung and cardiothoracic diseases, providing quantitative and personalized insights from X-ray and CT scans.

See all 1 product →

About 4DMedical

4DMedical is a global medical technology company that specializes in advanced software-based respiratory and cardiopulmonary imaging solutions. Their core offering, XV Technology®, utilizes patented algorithms derived from advanced aerodynamics research to process and enhance X-ray and Computed Tomography (CT) images. This technology allows for the dynamic quantification of regional lung ventilation and airflow throughout the entire respiratory cycle, providing clinicians with detailed, color-coded lung images and quantitative data in a report. This approach aims to detect subtle functional losses in the lungs earlier than traditional methods, potentially leading to more timely and effective treatment interventions.

For physicians, 4DMedical’s technology, delivered via a Software-as-a-Service (SaaS) model, integrates with existing imaging equipment, making it a non-invasive and accessible diagnostic tool. Key products include XV LVAS (X-ray Velocimetry Lung Ventilation Analysis Software) and CT LVAS (Computed Tomography Lung Ventilation Analysis Software), which provide insights into lung motion and airflow. Additionally, their CT:VQ™ product offers ventilation and perfusion insights from non-contrast CT imaging, comparable to SPECT V/Q studies but without the need for radioactive tracers. The company also offers a Lung Health Imaging Panel with components like LDAi (Lung Density Analysis–Inspiration) for emphysema assessment, CAC (Coronary Artery Calcification) for cardiovascular risk, and IQ-UIP for interstitial lung disease. 4DMedical’s solutions are designed to provide quantitative, actionable information to support diagnosis, disease monitoring, treatment planning, and surgical planning for a wide range of respiratory conditions, including those in veterans exposed to burn pits.

Focus Areas

respiratory imaging lung function analysis medical technology AI in healthcare quantitative imaging pulmonary diagnostics X-ray Velocimetry CT lung analysis ventilation-perfusion imaging

Business Intelligence

Key InvestorsCITICORP NOMINEES PTY LIMITED, State Street Global Advisors, JPMorgan Chase & Co., Vanguard Capital Management, BlackRock, Inc., Pro Medicus
PartnershipsSimonMed Imaging, SMS Biotech, multinational respiratory device company, Philips, RevealDx, Stanford University, Cleveland Clinic, University of Miami, UC San Diego Health, Brooke Army Medical Center
AcquisitionsImbio (2023), contextflow GmbH (2026)
Technologycloud-based, Software-as-a-Service (SaaS) delivery model, proprietary X-ray Velocimetry (XV Technology), AI-driven algorithms
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Respiratory Imaging & Lung Function Analysis
4DMedical specializes in advanced respiratory imaging, providing quantitative data on regional lung function and airflow. Their XV LVASu00ae (X-ray Velocimetry Lung Ventilation Analysis Software) and CT LVASu2122 (Computed Tomography Lung Ventilation Analysis Software) offer detailed insights into lung motion and ventilation, going beyond traditional structural imaging.
Medical Technology & AI in Healthcare
The company develops innovative medical technology, leveraging AI and proprietary algorithms to process and enhance X-ray and CT images. Their solutions provide automated, quantitative analysis to support diagnosis, care planning, and follow-up for patients with various lung conditions.
Quantitative Imaging & Pulmonary Diagnostics
4DMedical's core strength lies in quantitative imaging, delivering precise measurements of lung motion, airflow, and regional ventilation. This allows for earlier detection of subtle functional losses, potentially before irreversible structural damage occurs.
X-ray Velocimetry (XV Technology)
Their patented XV Technologyu00ae uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data, dynamically quantifying ventilation throughout the lungs. This technology is the foundation for their FDA-cleared XV LVASu00ae software.
CT Lung Analysis
4DMedical offers CT LVASu2122 and CT:VQu2122 which process non-contrast CT scans to provide functional lung health details, including regional lung motion, airflow, and ventilation-perfusion maps. CT LVASu2122 has been shown to provide results comparable to gold standard PET scans for assessing regional lung function.
Ventilation-Perfusion Imaging (CT:VQu2122)
CT:VQu2122 is the world's first FDA-cleared non-contrast, ventilation-perfusion imaging solution, transforming routine chest CTs into quantitative V/Q maps without injections or radioisotopes. This technology expands access to V/Q imaging, even in facilities without nuclear medicine capabilities.
Physician Tip

4DMedical's technologies provide physicians with unprecedented, objective, and data-driven insights into regional lung function and airflow, enabling earlier and more sensitive detection of respiratory deficiencies. This can lead to more precise and personalized treatment plans for conditions like COPD, asthma, cystic fibrosis, and pulmonary embolism, even revealing subtle forms of small airways disease missed by conventional tests. The non-invasive nature and compatibility with existing imaging equipment streamline workflows and reduce the need for contrast agents or radioisotopes, improving patient safety and accessibility. The detailed, color-coded reports and 4D video visualizations offer clear, actionable information for diagnosis, care planning, and monitoring disease progression.

4DMedical's solutions, including XV LVASu00ae, CT LVASu2122, and CT:VQu2122, are delivered as Software-as-a-Service (SaaS) and are designed to integrate seamlessly into existing clinical workflows. They process images from conventional X-ray and CT equipment, eliminating the need for new hardware. The results, including quantitative reports and visual maps, are routed directly to PACS for review, minimizing workflow disruption. 4DMedical also integrates anatomical nodule detection and AI risk scoring into their CT platform, allowing for automated risk stratification within a single PACS interface.

Products by 4DMedical

1 product in the directory

4DMedical (Imbio)
4DMedical
Cardiology AI
4DMedical, with its acquisition of Imbio, offers a comprehensive suite of AI-driven medical imaging solutions for chronic lung and cardiothoracic diseases, providing quantitative and personalized insights from X-ray and CT scans.

What the Web Says

4DMedical is a global medical technology company specializing in respiratory imaging and ventilation analysis through its XV Technology platform. The company's technology converts standard CT scans into dynamic lung function imaging, aiming to revolutionize the diagnosis and management of lung diseases. While the technology is considered innovative and has secured deployments with leading US academic medical centers, the company is still pre-profit and its high valuation is a point of discussion among investors.

Overall: Mixed

Strengths

  • Breakthrough and incredible technology for lung imaging and ventilation analysis.
  • Non-invasive and avoids contrasting chemicals or nuclear medicine.
  • High gross margins (87%) on its paper-scan cloud-delivered model.
  • Strong revenue growth, compounding at 128% per year since FY2021.
  • Clinical adoption gaining traction at prestigious institutions like Mayo Clinic, Stanford, and Cleveland Clinic.
  • Positive employee sentiment regarding work-life balance, pay, benefits, job security, management, and culture (from 4D Global Medical Billing Company reviews).

Limitations

  • High valuation despite being pre-profit and having relatively small absolute revenue.
  • Concerns about short-selling activity and stock overvaluation.
  • Product sales representatives may lack in-depth knowledge of the technology.
  • Potential for siloed data and issues with third-party support providers for their 4D EMR software (a different product/company, but sharing a similar name).
  • Management needs improvement (from 4D Global Medical Billing Company reviews).
  • Time and location flexibility, inclusive work environment, and trust in colleagues are areas for improvement (from 4D Global Medical Billing Company reviews).

Based on reviews from: Indeed.com, Reddit, AnnualReports.com, Capterra, Motley Fool, YouTube, Kalkine, Axis Imaging News, The Bull, G2

Last updated: 2026-08-06

Videos

News, demos, and interviews about 4DMedical.

Loading videos...

Videos load interactively. If none appear, search YouTube for 4DMedical →

View all on YouTube

Press & Coverage

4DMedical
4DMedical Welcomes Introduction of AIR CARE for Veterans Act
4DMedical has welcomed the introduction of the bipartisan AIR CARE for Veterans Act of 2026, which proposes a pilot program using FDA-approved four-dimensional functional lung imaging technology for veterans. This legislation aims to identify respiratory disorders and lung disease in veterans.
2026-08
HIT Consultant
4DMedical Invests $3.4M in RevealDx to Build a Connected Cardiopulmonary Platform
4DMedical has made a $3.4 million strategic investment in RevealDx, securing exclusive global distribution rights for RevealAI-Lung software. This partnership aims to create an integrated, PACS-native cardiopulmonary imaging platform and address the challenge of managing incidental lung nodules.
2026-08
4DMedical
4DMedical Receives TGA Approval for CT:VQu2122, Expanding Access to Functional Lung Imaging in Australia
4DMedical announced that its CT:VQu2122 technology has received Therapeutic Goods Administration (TGA) approval, allowing for commercial deployment across Australia. This makes CT:VQu2122 the first non-contrast CT-based ventilation-perfusion imaging solution available in the country.
2026-06
4DMedical
4DMedical Expands into Europe with Agreement to Acquire Software Lung Imaging Leader contextflow
4DMedical has signed an agreement to acquire contextflow GmbH, a Vienna-based medical software imaging company specializing in lung cancer detection and radiology workflow solutions. This acquisition establishes 4DMedical's European commercial platform.
2026-06
PR Newswire
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
4DMedical has secured over US$100 million (AU$150 million) in new institutional placement to accelerate U.S. adoption of its CT:VQu2122 product and boost research and development. This funding will primarily be used to scale hospital deployments and support early adopters.
2026-01
PR Newswire
4DMedical receives CE Mark for CT:VQu2122, enabling commercial launch across the European Union
4DMedical's CT:VQu2122 imaging technology has received CE Mark certification, allowing for its commercial launch across the European Union. This regulatory approval, combined with FDA clearance, enables rapid commercialization in major healthcare markets.
2026-03
Kalkine Media
4DMedical (ASX:4DX) Advances Precision Lung Care With New Clinical Validation
A peer-reviewed study on 4DMedical's CT:VQ platform was published in the American Journal of Respiratory and Critical Care Medicine, indicating that CT:VQ-guided patient selection could significantly improve lung volume reduction surgery response rates. The research was also presented at the ATS International Conference 2026.
2026-05
4DMedical
4DMedical Signs Distribution Agreement with Blackford
4DMedical has signed an agreement with Blackford Analysis Inc. to distribute Imbio's medical imaging AI solutions. This partnership aims to expand the reach of AI-driven imaging capabilities for chronic lung and cardiothoracic diseases.
2024-02

Frequently Asked Questions

4DMedical's XV Technology is designed to quantitatively assess regional lung motion and airflow, providing insights into conditions such as asthma, COPD, cystic fibrosis, and long COVID. Unlike spirometry, which offers global lung function, or CT scans, which provide anatomical snapshots, XV Technology offers dynamic, regional ventilation information without the high radiation dose of repeated CTs.
4DMedical adheres to stringent regulatory standards for medical devices, holding clearances from bodies like the FDA in the US and TGA in Australia. They implement robust data security and privacy protocols to comply with regulations such as HIPAA and GDPR, ensuring patient information is protected while maintaining high standards for diagnostic accuracy through rigorous validation studies.
While specific pricing varies based on the product and institutional needs, 4DMedical generally offers flexible models, potentially including per-scan fees or subscription-based access to their software and analysis platforms. They provide comprehensive support, including on-site training, technical assistance, and ongoing education to ensure seamless integration into clinical workflows and optimal utilization of their technology.
4DMedical's AI-powered lung analysis tools are designed for interoperability and can integrate with most existing Picture Archiving and Communication Systems (PACS) and Electronic Medical Record (EMR) systems. Implementation typically requires standard network connectivity and adherence to specified hardware and software requirements, which are detailed during the pre-installation assessment to ensure compatibility and smooth operation.
4DMedical has established partnerships with various healthcare providers, research institutions, and technology companies to advance their respiratory imaging solutions. These collaborations often involve clinical trials, research initiatives, and co-development efforts, which enhance the validation of their technology, expand their product offerings, and contribute to their market stability and credibility within the healthcare industry.

Investors

Who's funded 4DMedical.

Related Companies

Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]

Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]

Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]

Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]

Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]

SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.